Opus Genetics, Inc. (IRD) Financial Analysis & Valuation | Quarter Chart
Opus Genetics, Inc. (IRD)
IRDPrice: $4.84
Fair Value: 🔒
🔒score
Opus Genetics, Inc., a clinical-stage ophthalmic biopharmaceutical company, focuses on developing and commercializing therapies for the treatment of unmet needs of patients with refractive and retinal eye disorders. The company offers Phentolamine Ophthalmic Solution for reversal of mydriasis, as we... more
Opus Genetics, Inc., a clinical-stage ophthalmic biopharmaceutical company, focuses on developing an... more
Description
Shares
| Market Cap | $333.79M | Exchange | NASDAQ |
| Sector | Healthcare | Industry | Biotechnology |
| Country | US | CEO | George Magrath |
| IPO Date | 2015-01-19 | CAGR | — |
| Employees | 18 | Website | opusgtx.com |
| Div. Yield | — | Payout Ratio | — |
| Buy Back Yield | — | Total Yield | — |
IRD chart loading...
Fundamentals
Technicals
| Enterprise Value | $243.88M | P/E Ratio | -2.6 |
| Forward P/E | -10.04 | PEG Ratio | — |
| P/S Ratio | 76600893594.25 | P/B Ratio | 71539761260.98 |
| P/CF Ratio | -39082778650.16 | P/FCF Ratio | -37202610831.96 |
| EPS | $-1.86 | EPS Growth 1Y | 56.36% |
| EPS Growth 3Y | 47.01% | EPS Growth 5Y | — |
| Revenue Growth 1Y | 37.86% | Gross Margin | 0.81% |
| Operating Margin | -4.21% | Profit Margin | -3.78% |
| ROE | -3.67% | ROA | -1.51% |
| ROCE | -3.51% | Current Ratio | 1.9 |
| Quick Ratio | 1.9 | Cash Ratio | 1.61 |
| Debt/Equity | — | Interest Coverage | -46.11 |
| Altman Z Score | 0.42 | Piotroski Score | 2 |